Long-range recurrence of gliomas is associated with the development of the lower part of the brain and CD133

Glioblastoma (GBM) is the most common primary malignancy of the central nervous system in adults.
the current standard of treatment, GBM patients have a medium survival of 18 months.
relapse is common after treatment.
that even after surgery, the tumor was well controlled at the initial lesions site, but the recurrence rate at the remote site was between 8% and 43.6%.
stem cells (Cancer Stem Cell, CSC) in GBM can induce tumor occurrence and differentiation.
CSC has the ability to metastasis and resist chemotherapy.
CSC marker CD133 has now been detected from normal mouse and human stem cells.
CD133 is expressed not only in normal stem cells, but also in many cancer stem cells.
Tatsu Yamaki of Neurosurgery at Yamash prefecture university in Japan, et al. further studied the correlation between CD133 expression and GBM-tired ventricular region (subventrication zone, SVZ) and GBM long-range recurrence, and published online in February 2020 in NeuroJcolon.
methods The researchers retrospectively analyzed data on 167 GBM patients.
the spatial relationship between the tumor and SVZ or cortical on MRI enhancement imaging, the tumor was divided into four groups.
I. Group: Tumor-tired SVZ region, adjacent to and immersed cortique; II.group: tumor-tired and SVZ region, but not immersed cortique; III.group: tumor not tired and SVZ region, but impregnation cortique; IV.group: tumor not tired and SVZ region, also not immersed corted (Figure 1).
the initial recurrence mode of GBM from the patient's medical records.
Factors for predicting long-range recurrence are determined by analyzing patient clinical information (including age, sex, KPS, Ki-67 marker index, surgical and MRI characteristics, etc.), immunogroupization results of tumor specimens, genetic characteristics (including IDH1, MGMT, and BRAF testing), and CD133 expression.
1. Based on MRI imaging to show the relationship between tumors and the brain chamber, patients were divided into 4 groups.
A.I. Group: Tumor-tired SVZ region, adjacent to and soaked cortique; B.II.group: tumor-affected SVZ region, but not immersed cortique; C.III.group: tumor not tired and SVZ region, but leaching cortique; D.IV.group: Tumors neither affected SVZ region nor soaked cortique.
results showed that the CD133 expression rate of tumors in the SVZ region was higher than that of tumors in the SVZ region .
21% of patients had long-range recurrence, and no significant differences were found in 4 groups of recurrence patterns.
analysis of single variables, multivariables, and tendency matching shows that the high expression of CD133 is related to the earlier occurrence of long-range recurrence (P<0.0001, P.001 and P.0084, respectively).
In a comprehensive analysis of the four sets of recurrence patterns shown in CD133 expression and MRI, it was found that CD133 expression levels ≥15% of group III. Group III. that GBM, which is not tired of the SVZ region and soaked in cort matter, is most commonly relapsed over long distances (70%) (Figure 2).
Figure 2. CD133 expression combined with tumor MRI characteristics to predict long-range recurrence rates.
The study showed that combined with GBM's CD133 expression level and mri imaging to show a comprehensive analysis of tumor-tired regions, it helped to predict GBM's long-range recurrence.
: The intellectual property rights of the content published by the Brain Medical Exchange's Extra-God Information, God-based Information and Brain Medicine Consulting are owned by the Brain Medical Exchange and the organizers, the original authors and other relevant rights persons.
, editing, copying, cutting, recording, etc. without permission.
be used with a license, the source must also be indicated.
welcome to forward and share.
。